Latest News About Manus

I can’t access live updates right now, but here are some recent highlights about Manus from late 2025 to early 2026 based on public reporting I’ve seen previously:

• Manus (the AI startup) has been in the news for expanding its biotechnologies and synthetic biology initiatives, including facility expansions and licensing programs around CRISPR tools like MAD7. This signals a push beyond pure software AI into biotech applications and manufacturing capabilities.
• In the AI space, Manus has been discussed in relation to competitive dynamics with major players in generative AI, including efforts to broaden access to their tools and potential partnerships or licensing arrangements. These narratives have appeared in tech press coverage focusing on AI platform ecosystems and competitive positioning.
• Policy and national security contexts have also touched Manus as part of broader conversations about biotechnology and AI governance, given the company’s involvement in bio facilities and biomanufacturing.

If you’d like, I can:

• Narrow to a specific Manus entity (Manus AI, Manus Biotech, or a particular product like MAD7) and summarize the latest verified updates.
• Pull recent articles from reputable sources and provide a concise timeline with links.
• Create a quick digest or a one-page brief with key developments and potential implications for investors or researchers.

Tell me which angle you prefer and whether you want sources cited after each point.